Shree Hanuman Sg (537709)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Book value of ₹73.17 per share versus market price of ₹12.29 gives a P/B of 0.17, implying an 83% discount to net worth.
• Market cap of ₹23 crore is small enough that a modest capital infusion or turnaround could move the needle significantly.
• ROE and ROCE are only marginally negative at -0.60% and -0.20%, so the asset base is not being rapidly eroded.
• The stock is at its 52-week high of ₹12.29, indicating some recent buying interest or hope of revival.

Concerns

• Latest quarter sales are ₹0 Cr and net profit is ₹-0 Cr, meaning there is no visible operating earnings engine.
• Piotroski F-score of 2/9 points to weak financial health and poor fundamental momentum.
• No dividend, no sales growth, and profit growth of -111.11% leave shareholders with zero current return.
• Promoter holding and debt/equity data are unavailable, creating a serious transparency issue for minority investors.

AI Analysis

I approach investing like buying a rupee for forty cents. Here, the market offers ₹73.17 of book value for a share at ₹12.29 — roughly 17 paise per rupee. That catches any Graham-style investor’s attention. But the business side is deeply discouraging. This is a sugar company with zero sales in the latest quarter and a net profit that rounds to zero. Sales growth is 0.00%, profit growth is -111.11%, and the P/E is meaningless at 0.00 because there are no real earnings. Return on equity is -0.60%, and return on capital employed is -0.20%. The Piotroski F-score is 2 out of 9, so the reported financial health is poor. There is no dividend, no revenue growth, and no profitability to speak of. At a market cap of only ₹23 crore, this is a tiny microcap, and that creates both opportunity and risk. In Buffett terms, I would rather have a wonderful business at a fair price than a mediocre asset at a cheap price. This may be a cigar butt: one puff left if asset values are realised or the sugar cycle turns. But with promoter holding not available and inadequate data, I cannot judge whether minority shareholders will benefit. The stock is at its 52-week high of ₹12.29, up from ₹3.80, so the market may already be pricing hopes. I need evidence of real sales, positive operating margins, and honest capital allocation. Until then, this remains a speculative asset play, not a compounding machine. I will stay cautious.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer